We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ACC.24 - In the PREVENT trial, preventive PCI plus optimal medical therapy (OMT) was superior to OMT alone for reducing cardiac events in patients with non–flow-limiting vulnerable coronary plaques. Marc Bonaca, the discussant of the PREVENT trial, reviews the results.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Marc Bonaca, MD is a Cardiologist and Vascular Medicine Specialist and is the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 15 april 2024
ACC.24 - In the PREVENT trial, preventive PCI plus optimal medical therapy (OMT) was superior to OMT alone for reducing cardiac events in patients with non–flow-limiting vulnerable coronary plaques. Marc Bonaca, the discussant of the PREVENT trial, reviews the results.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Marc Bonaca, MD is a Cardiologist and Vascular Medicine Specialist and is the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 15 april 2024
Stay current with the best on medical education
